Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results
Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines
CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype.
The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines.
'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.'
The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline.
The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting.
Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 hours ago
- Business Wire
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. 'The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.' Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of the combination of zanzalintinib in combination with atezolizumab to improve overall survival in patients with metastatic CRC; Exelixis' plans to discuss the trial data from STELLAR-303 with regulatory authorities and to present detailed findings at an upcoming medical conference; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group. ___________________________ 1 Key Statistics for Colorectal Cancer. ACS website. Available at: Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806.
Boston Globe
15 hours ago
- Boston Globe
Mass. considers scrapping religious exemptions for vaccinations
Advertisement In Massachusetts, parents can write a letter stating that a vaccine conflicts with their 'sincerely held religious belief' in order to exempt their children from vaccination requirements needed to enroll in public schools. State Rep. Andy Vargas and State Sen. Edward Kennedy both Advocates who oppose the exemptions say that religious exceptions are being misused by parents who are hesitant about vaccinating their children. Advertisement 'It's definitely a general pattern of people abusing the exemption, especially since But parents across the state came to Beacon Hill to testify in support of religious exemptions at a hearing of the Legislature's Joint Committee on Public Health. They said exemptions were essential to their first amendment right to practice their religion and to honor the concept of informed consent. 'I'm curious why diversity, equity and inclusion is not being applied to those with sincerely held religious beliefs,' Lisa Ottaviano said while testifying at the hearing. Some speakers at the hearing said they were uncomfortable with the components of certain vaccines. 'We should not be forced into violating our moral conscience by injecting products developed from aborted fetuses such as the MMR, the varicella vaccines,' said Nicholas Kottenstette, a Catholic father of four from Sterling, Massachusetts. Vaccines don't contain fetal cells, Others testifying against the bill said they wanted to protect religious exemptions because they felt that accountability measures for vaccine manufacturers were insufficient. 'I started meeting more people whose children had reactions to vaccines that were adverse, so I started doing my own research and learnt a lot of concerning things like how pharmaceutical companies have legal protection against being sued,' Maureen Trettel, a grandmother from Milford said. Advertisement Similar bills have been filed in previous sessions, so the debate over religious exemptions for vaccines in Massachusetts has been going on since at least 2019, well before the COVID-19 pandemic that made vaccines a polarizing issue. The elevation of Robert F. Kennedy Jr., a vaccine skeptic, to U.S. Secretary of Health and Human Services has drawn even more interest to the issue. Last week, Kennedy Logan Beyer, an aspiring pediatrician pursuing an MD/PhD degree in public health at Harvard, spoke in favor of eliminating religious exemptions. While volunteering at a Special Olympics event, Beyer spoke to a parent who told her that she was worried that vaccines caused autism. The mother told Beyer that she was planning to apply for a religious exemption because she was unsure about vaccinating her children. 'She told me that her family 'didn't really go to church' but you don't have to prove anything to get the exemption,' Beyer said. Beyer said that this incident made her concerned about growing vaccine hesitancy and inspired her to testify. 'At the hearing, so many parents said they just want to do what's best for their children … I love that instinct,' Beyer said, 'But I know that passing policies that help facilitate more kids getting vaccinated is really what can keep children safe.' Advertisement Harrison, mother of cancer-survivor Miranda, also understands the instinct of parents on the other side of the issue, even if she disagrees with them. In addition to Miranda, Harrison has twin six-year old boys who both have autism. 'I can know the grief and shock that parents experience when they find out their kid has autism. I get it,' Harrison said. 'But vaccines are not to blame ... autism is a result of Around 16,000 children in Massachusetts are unvaccinated without claiming an exemption — a group that the state describes as 'noncompliant students' in its documents. Many parents in opposition to the bills questioned why the bills were trained just on the 2,000 students who did have religious exemptions. 'I'm curious why the Legislature is targeting the small percentage of children with religious exemptions and ignoring the huge gap population,' said Ottaviano testifying at the hearing. Advocates for the bills said the new provisions that mandate that all schools must report vaccination numbers to the state's department of public health would address these noncompliant students as well. 'That's what the data reporting is about, we want to make sure that schools have accurate records,' Blair of Massachusetts Families for Vaccines said. 'If there is a gap … they should reach out to those students to find out why the records are not on file.' Speakers in favor of the bills were focused on eliminating religious exemptions in order to protect children who cannot be vaccinated due to medical reasons like allergies or problems with their immune systems. 'It's actually those people … that we're really doing this for, because they're the ones who depend on herd immunity,' Blair said. Advertisement Angela Mathew can be reached at
New York Times
20 hours ago
- New York Times
‘I Feel Like I've Been Lied To': When a Measles Outbreak Hits Home
He was a chiropractor by training, but in a remote part of West Texas with limited medical care, Kiley Timmons had become a first stop for whatever hurt. Ear infections. Labor pains. Oil workers who arrived with broken ribs and farmers with bulging discs. For more than a decade, Kiley, 48, had seen 20 patients each day at his small clinic located between a church and a gas station in Brownfield, population 8,500. He treated what he could, referred others to physicians and prayed over the rest. It wasn't until early this spring that he started to notice something unfamiliar coming through the door: aches that lingered, fevers that wouldn't break, discolored patches of skin that didn't make sense. At first, he blamed it on a bad flu season, but the symptoms stuck around and then multiplied. By late March, a third of his patients were telling him about relatives who couldn't breathe. And then Kiley started coughing, too. His wife, Carrollyn, had recently tested positive for Covid, but her symptoms eased as Kiley's intensified. He went to a doctor at the beginning of April for a viral panel, but every result came back negative. The doctor decided to test for the remote possibility of measles, since there was a large outbreak spreading through a Mennonite community 40 miles away, but Kiley was vaccinated. 'I feel like I'm dying,' Kiley texted a friend. He couldn't hold down food or water. He had already lost 10 pounds. His chest went numb, and his arms began to tingle. His oxygen was dropping dangerously low when he finally got the results. 'Positive for measles,' he wrote to his sister, in mid-April. 'Just miserable. I can't believe this.' Twenty-five years after measles was officially declared eliminated from the United States, this spring marked a harrowing time of rediscovery. A cluster of cases that began at a Mennonite church in West Texas expanded into one of the largest outbreaks in a generation, spreading through communities with declining vaccination rates as three people died and dozens more were hospitalized from Mexico to North Dakota. Public health officials tracked about 1,200 confirmed cases and countless exposures across more than 30 states. People who were contagious with measles boarded domestic flights, shopped at Walmart, played tuba in a town parade and toured the Mall of America. Want all of The Times? Subscribe.
